Status:
RECRUITING
The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Conditions:
Lung Cancer
Artificial Intelligence (AI)
Eligibility:
All Genders
40-74 years
Phase:
NA
Brief Summary
AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in n...
Detailed Description
Artificial intelligence (AI) technologies, particularly advanced medical imaging analysis systems like the AI diagnostic platform evaluated in this study, demonstrate significant potential for enhanci...
Eligibility Criteria
Inclusion
- Aged 45-74 years
- Permanent resident of participating study communities
- No prior history of lung cancer and no lung cancer screening within the past 3 months
- Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-up
Exclusion
- Individuals with a confirmed diagnosis of lung cancer
- Those with severe comorbidities contraindicating CT imaging
- Inability to understand study protocols or provide informed consent due to cognitive impairment
- Concurrent participation in other clinical trials that may interfere with study outcomes
- Unable to comply with follow-up requirements
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 7 2026
Estimated Enrollment :
7294 Patients enrolled
Trial Details
Trial ID
NCT06988579
Start Date
July 1 2024
End Date
January 7 2026
Last Update
June 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital of Guangzhou Medical University,
Guangzhou, Guangdong, China, 510120